Pulse Biosciences (PLSE) Cash & Equivalents (2015 - 2025)

Pulse Biosciences' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $80.7 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 31.63% year-over-year to $80.7 million in Q4 2025; TTM through Dec 2025 was $80.7 million, a 31.63% decrease from a year earlier, with the FY2025 full-year figure at $80.7 million, down 31.63% from the prior year.
• Cash & Equivalents slipped to $80.7 million in Q4 2025 per PLSE's latest filing, from $95.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $119.3 million in Q1 2025 and bottomed at $12.7 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $55.2 million (2023), against an average of $60.7 million.
• Across the five-year window, Cash & Equivalents soared 661.48% in 2021 and slumped 78.83% in 2022, its largest moves.
• Year by year, Cash & Equivalents stood at $44.4 million in 2021, then soared by 30.67% to $58.0 million in 2022, then retreated by 23.47% to $44.4 million in 2023, then jumped by 166.06% to $118.0 million in 2024, then slumped by 31.63% to $80.7 million in 2025.
• Per Business Quant, the three latest PLSE Cash & Equivalents figures stand at $80.7 million (Q4 2025), $95.2 million (Q3 2025), and $106.3 million (Q2 2025).